Key result
Both atorvastatin and cerivastatin effectively lowered LDL cholesterol, but atorvastatin increased cyclosporin A blood trough levels in 4 of 10 patients, whereas cerivastatin did not.
Why the study?
Do atorvastatin or cerivastatin lower lipid levels and affect cyclosporin A blood trough levels in CsA-treated renal transplant recipients?
RCT (n=30)
randomly assigned
Do atorvastatin or cerivastatin lower lipid levels and affect cyclosporin A blood trough levels in CsA-treated renal transplant recipients?
In CsA-treated renal transplant recipients, both atorvastatin and cerivastatin effectively lower lipids, but atorvastatin may increase CsA blood trough levels, requiring careful monitoring.
No takes yet. Share an insight, caveat, or question.
Atorvastatin warrants CsA trough monitoring in renal transplant recipients; RCT extends evidence of statin-specific interactions.
Renders et al. (2001) conducted an RCT in Hyperlipidaemia in renal transplant recipients (n=30). Atorvastatin and cerivastatin vs. Control group was evaluated on Cyclosporin A (CsA) blood trough levels and lipid levels. Both atorvastatin and cerivastatin effectively lowered LDL cholesterol, but atorvastatin increased cyclosporin A blood trough levels in 4 of 10 patients, whereas cerivastatin did not.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: